Some content of this application is unavailable at the moment.
If this situation persist, please contact us atFeedback&Contact
1. (WO2017153381) CHROMOGRANIN A AS A MARKER FOR BLADDER CANCER
Latest bibliographic data on file with the International Bureau    Submit observation

Pub. No.: WO/2017/153381 International Application No.: PCT/EP2017/055279
Publication Date: 14.09.2017 International Filing Date: 07.03.2017
IPC:
G01N 33/574 (2006.01)
G PHYSICS
01
MEASURING; TESTING
N
INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
33
Investigating or analysing materials by specific methods not covered by groups G01N1/-G01N31/131
48
Biological material, e.g. blood, urine; Haemocytometers
50
Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
53
Immunoassay; Biospecific binding assay; Materials therefor
574
for cancer
Applicants:
CÉZANNE S.A.S. [FR/FR]; 280 Allée Graham Bell Parc Scientifique Georges Besse 30035 Nîmes Cédex 1, FR
Inventors:
JARDIN-WATELET, Bénédicte; FR
BOURGOIN, Nicolas; FR
SZARVAS, Tibor; HU
Agent:
VOSSIUS & PARTNER; Siebertstraße 3 81675 München, DE
Priority Data:
16159474.209.03.2016EP
Title (EN) CHROMOGRANIN A AS A MARKER FOR BLADDER CANCER
(FR) CHROMOGRANINE A COMME MARQUEUR DU CANCER DE LA VESSIE
Abstract:
(EN) The present invention relates to the use of Chromogranin A (CgA) as a marker (particularly a prognostic marker) for bladder cancer, particularly non-neuroendocrine bladder cancer and preferably urothelial carcinoma. In particular, CgA can be used as a marker in an in vitro assay for the prognosis, risk assessment, risk stratification, monitoring and/or therapy control of bladder cancer (particularly non-neuroendocrine bladder cancer, preferably urothelial carcinoma). The invention further pertains to a method for the prognosis, risk assessment, risk stratification, monitoring and/or therapy control of bladder cancer (particularly non-neuroendocrine bladder cancer, preferably urothelial carcinoma) in a subject, comprising the step of determining the level of CgA and optionally MMP7 in a sample of a bodily fluid of said subject.
(FR) La présente invention concerne l'utilisation de la Chromogranine A (CgA) comme marqueur (en particulier comme marqueur pronostique) pour le cancer de la vessie, en particulier pour le cancer de la vessie non neuroendocrinien et de préférence le carcinome urothélial. En particulier, la CgA peut être utilisée comme marqueur dans un essai in vitro pour le pronostic, l'évaluation des risques, la stratification du risque, la surveillance et/ou le contrôle thérapeutique du cancer de la vessie (en particulier du cancer de la vessie non neuroendocrinien, de préférence le carcinome urothélial). L'invention concerne en outre un procédé pour le pronostic, l'évaluation des risques, la stratification du risque, la surveillance et/ou le contrôle thérapeutique du cancer de la vessie (en particulier du cancer de la vessie non neuroendocrinien, de préférence le carcinome urothélial) chez un sujet, comprenant l'étape consistant à déterminer le niveau de CgA et éventuellement de MMP7 dans un échantillon d'un fluide corporel dudit sujet.
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
African Regional Intellectual Property Organization (ARIPO) (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Office (AM, AZ, BY, KG, KZ, RU, TJ, TM)
European Patent Office (EPO) (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG)
Publication Language: English (EN)
Filing Language: English (EN)